Search

Your search keyword '"Whalen, Jeanne"' showing total 542 results

Search Constraints

Start Over You searched for: Author "Whalen, Jeanne" Remove constraint Author: "Whalen, Jeanne" Publisher dow jones & company, inc. Remove constraint Publisher: dow jones & company, inc.
542 results on '"Whalen, Jeanne"'

Search Results

1. In England, girls are closing gap with boys in math' making class interactive has side effect: females thrive; echoes of Harvard debate

2. FDA seizes two Glaxo drugs on production-quality concerns

3. Novartis expands generics range for $8.4 billion; acquisition of two firms aims at growing demand for broader drug portfolio

4. Big Pharma, flush with cash, is looking acquisitive

5. Demand lags for Viagra and its rivals

6. WHO crisis team scrambles to fight disease outbreaks

7. Competing with big pharma; three midsize drug makers are faring better than larger rivals

8. AstraZeneca plans an overhaul after latest product setback

9. New leukemia drugs may prove more potent than Gleevec

10. Generic maker pulls HIV drugs from WHO use

11. Merck's earnings are hurt by Vioxx, Lilly reports higher profit but sales of Zyprexa sink; Novartis, others post gains

12. New flu worry: antiviral drugs also may be in short supply

13. Contagious turmoil; closing of flu-vaccine plant by British regulators took Chiron, U.S. by surprise

15. AstraZeneca needs R&D magic; Exanta and Crestor setbacks put pressure on product pipeline

16. Alternative medicine: a big drug maker moves to play down mass-market pills; Roche seeks pricey products in specialties like cancer and rejects megamergers; Pfizer's edge in sales muscle

17. Clinical trials get tighter security; medical journals decide against publishing results unless study has registered

18. Sanofi-Synthelabo's net rises; Bayer profit is flat due to write-off of firm's stake in venture

19. Eli Lilly profit falls on charges; AstraZeneca net climbs 25%

20. Drug firms post mixed results; Pfizer records strong earnings; Merck, Wyeth slip

21. Doctor defends linking suicide, antidepressants

22. Novartis shares belie growth; bulls shrug off merger uncertainty, citing smart moves in past

23. Glaxo CEO: litigation is 'getting out of control'

24. AstraZeneca looks within; drug maker won't rely on mergers or acquisitions to grow

25. Belgian drug company beefs up to take on U.S. biotech rivals

28. Sanofi-Aventis deal could spur other mergers; drug makers are facing patent-expiration pressure as lab productivity falls

29. Tough drill: for West's oil giants, vast fields in Russia prove hard to tap; Exxon Mobil's awkward dance with Moscow show perils; Putin's veiled warnings; a tycoon remains in jail

31. Third party may enter Yukos talks; participants in deal weigh pulling in Western oil firm to purchase Sibneft stake

32. Yukos and Sibneft to unwind plans for oil merger

33. Russian oil-output growth slows

36. Balance of power: China's growing thirst for oil remakes the global market; Beijing's buying keeps prices high - and could reshape politics of Middle East; growing closer to the Saudis

37. New pressures on Yukos deal seen from Kremlin

38. Russia may reject Kyoto Protocol in 'current form.'

39. Yukos would cede management jobs to rescue merger

40. Sibneft calls halt to Yukos merger as feud intensifies

41. Russia to shutter tax havens in bid for oil revenue

42. BP moves forward on Siberian gas venture

44. Kremlin official questions freeze of Yukos shares; Putin chief of staff warns prosecutors to consider economic fallout of moves

46. American finds himself atop Russian oil giant in turmoil

50. Russia seeks economic guarantee in Kyoto Pact

Catalog

Books, media, physical & digital resources